Elliptinium: phase II study in advanced measurable breast cancer.

Abstract

Eighteen patients with advanced measurable breast cancer were treated with elliptinium acetate 100 mg/m2 x 3 days every 3 weeks. Fourteen of these patients had failed prior chemotherapy. Two patients had an objective tumor response of greater than 4 weeks. Myelosuppression, renal insufficiency and thrombophlebitis were rarely encountered and alopecia was not seen at all. This study demonstrates that elliptinium has minimal activity in recurrent breast cancer with a favorable toxicity profile.

• Authors: J Treat, A Greenspan, A Rahman, M S McCabe, P J Byrne
• Journal: Investigational new drugs (Invest New Drugs) Vol. 7 Issue 2-3 Pg. 231-4 (Jul 1989) ISSN: 0167-6997 [Print] United States
• PMID: 2793378 (Publication Type: Journal Article)

Chemical References

• Alkaloids
• Antineoplastic Agents
• Ellipticines
• elliptinium

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Alkaloids (therapeutic use)
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Ellipticines (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Middle Aged
• Neoplasm Metastasis